Case-Control Breast Cancer Study of MALDI-TOF Proteomic Mass Spectrometry Data on Serum Samples

We introduce mass spectrometry proteomic research for diagnosis from a clinical perspective, with special reference to early-stage breast cancer detection. The nature of SELDI and MALDI mass spectrometric measurement is discussed. We explain how the mass spectral data arising from this technology ma...

Full description

Saved in:
Bibliographic Details
Published inStatistical applications in genetics and molecular biology Vol. 7; no. 2; p. 1352
Main Authors van der Werff, Martijn P J, Mertens, Bart, de Noo, Mirre E, Bladergroen, Marco R, Dalebout, Hans C, Tollenaar, Rob A E M, Deelder, Andre M
Format Journal Article
LanguageEnglish
Published 25.01.2008
Online AccessGet full text

Cover

More Information
Summary:We introduce mass spectrometry proteomic research for diagnosis from a clinical perspective, with special reference to early-stage breast cancer detection. The nature of SELDI and MALDI mass spectrometric measurement is discussed. We explain how the mass spectral data arising from this technology may be viewed as a new data type. Some of the properties of the data are discussed and we show how such spectra may be interpreted. Sample preprocessing for mass spectrometry is introduced and a literature review of research in clinical proteomics is presented. Finally, we provide a detailed description of the study design on the breast cancer case-control study which is investigated in this special issue.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ISSN:1544-6115